John Scott Roth, MD, FACS

Prof. John Scott Roth, MD, FACS

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2017 in Surgical Endoscopy
Verified
Journal Article
Closed access
JFJohn Scott Roth, MD, FACS
John Scott Roth, MD, FACS
GAGary J. Anthone
Gary J. Anthone
DSDon J. Selzer
Don J. Selzer
BPBenjamin K. Poulose
Benjamin K. Poulose
JBJames G. Bittner
James G. Bittner
GVGuy R. Voeller
Guy R. Voeller

1 May 2020 in Surgical Infections
Verified
Journal Article
Closed access
MPMargaret A. Plymale
Margaret A. Plymale
DDDaniel L. Davenport
Daniel L. Davenport
SWSeth Walsh-Blackmore
Seth Walsh-Blackmore
JHJordan Hess
Jordan Hess
WGWilliam Scott Griffiths
William Scott Griffiths
JFJohn Scott Roth, MD, FACS
John Scott Roth, MD, FACS
Background: Mesh hernia repair is widely accepted because of the associated reduction in hernia recurrence compared with suture-based repair. Despite initiatives to reduce risk, mesh infection and mesh removal are a significant challenge. In an era of healthcare value, it is essential to understand the global cost of care, including the incidence and cost of complications. The purpose of this study was to identify the outcomes and costs of care of patients who required the removal of infected hernia mesh. Methods: A review of databases from 2006 through June 2018 identified patients who underwent both ventral hernia repair (VHR) and re-operation for infected mesh removal. Patient demographic and operative details for both procedures, including age, Body Mass Index, mesh type, amount of time between procedures, and information regarding interval procedures were obtained. Clinical outcome measures were the length of the hospital stay, hospital re-admission, incision/non-incision complications, and re-operation. Hospital cost data were obtained from the cost accounting system and were combined with the clinical data for a cost and clinical representation of the cases. Results: Thirty-four patients underwent both VHR and removal of infected mesh material over the 12-year time frame and were included in the analyses; the average age at VHR was 48 years, and 16 patients (47%) were female. Following VHR, 21 patients (62%) experienced incision complications within 90 days post-operatively, the complications ranging from superficial surgical site infection (SSI) to evisceration. A mean of 22.65 months passed between procedures. After mesh removal, 16 patients (47%) experienced further incisional complications; and 22 (65%) patients had at least one re-admission. Eighteen patients (53%) required a minimum of one additional related operative procedure after mesh removal. Median hospital costs nearly doubled (p < 0.001) for the mesh removal ($23,841 [interquartile range {IQR} $13,596–$42,148]) compared with the VHR admission ($13,394 [IQR $8,424–$22,161]) not accounting for re-admission costs. A majority experienced hernia recurrence subsequent to mesh removal. Conclusions: Mesh infection after hernia repair is associated with significant morbidity and costs. Hospital re-admission, re-operations, and recurrences are common among these patients, resulting in greater healthcare resource utilization. Development of strategies to prevent mesh infection, identify patients most likely to experience infectious complications, and define best practices for the care of patients with mesh infection are needed.

10 June 2016 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MPMargaret A. Plymale
Margaret A. Plymale
RRRanjan Ragulojan
Ranjan Ragulojan
DDDaniel L. Davenport
Daniel L. Davenport
JFJohn Scott Roth, MD, FACS
John Scott Roth, MD, FACS

15 September 2017 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MPMargaret A. Plymale
Margaret A. Plymale
DDDaniel L. Davenport
Daniel L. Davenport
ADAdam Dugan
Adam Dugan
AZAmanda Zachem
Amanda Zachem
JFJohn Scott Roth, MD, FACS
John Scott Roth, MD, FACS

17 August 2022 in Journal of the American College of Surgeons
Verified
Journal Article
Open access
JFJohn Scott Roth, MD, FACS
John Scott Roth, MD, FACS
GAGary J Md Anthone
Gary J Md Anthone
DSDon J Md Selzer
Don J Md Selzer
BPBenjamin K Md Poulose
Benjamin K Md Poulose
RPRichard A Pierce
Richard A Pierce
GVGuy R Md Voeller
Guy R Md Voeller
BACKGROUND: Long-term resorbable mesh represents a promising technology for ventral and incisional hernia repair (VIHR). This study evaluates poly-4-hydroxybutyrate mesh (P4HB; Phasix Mesh) among comorbid patients with CDC class I wounds. STUDY DESIGN: This prospective, multi-institutional study evaluated P4HB VIHR in comorbid patients with CDC class I wounds. Primary outcomes included hernia recurrence and surgical site infection. Secondary outcomes included pain, device-related adverse events, quality of life, reoperation, procedure time, and length of stay. Evaluations were scheduled at 1, 3, 6, 12, 18, 24, 30, 36, and 60 months. A time-to-event analysis (Kaplan-Meier) was performed for primary outcomes; secondary outcomes were reported as descriptive statistics. RESULTS: A total of 121 patients (46 male, 75 female) 54.7 ± 12.0 years old with a BMI of 32.2 ± 4.5 kg/m2 underwent VIHR with P4HB Mesh (mean ± SD). Fifty-four patients (44.6%) completed the 60-month follow-up. Primary outcomes (Kaplan-Meier estimates at 60 months) included recurrence (22.0 ± 4.5%; 95% CI 11.7% to 29.4%) and surgical site infection (10.1 ± 2.8%; 95% CI 3.3 to 14.0). Secondary outcomes included seroma requiring intervention (n = 9), procedure time (167.9 ± 82.5 minutes), length of stay (5.3 ± 5.3 days), reoperation (18 of 121, 14.9%), visual analogue scale–pain (change from baseline –3.16 ± 3.35 cm at 60 months; n = 52), and Carolinas Comfort Total Score (change from baseline –24.3 ± 21.4 at 60 months; n = 52). CONCLUSIONS: Five-year outcomes after VIHR with P4HB mesh were associated with infrequent complications and durable hernia repair outcomes. This study provides a framework for anticipated long-term hernia repair outcomes when using P4HB mesh.

1 January 2021 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
JFJohn Scott Roth, MD, FACS
John Scott Roth, MD, FACS
GAGary J. Anthone
Gary J. Anthone
DSDon J. Selzer
Don J. Selzer
BPBenjamin K. Poulose
Benjamin K. Poulose
RPRichard A. Pierce
Richard A. Pierce
GVGuy R. Voeller
Guy R. Voeller
This study represents a prospective, multicenter, open-label study to assess the safety, performance, and outcomes of poly-4-hydroxybutyrate (P4HB, Phasix™) mesh for primary ventral, primary incisional, or multiply-recurrent hernia in subjects at risk for complications. This study reports 3-year clinical outcomes. P4HB mesh was implanted in 121 patients via retrorectus or onlay technique. Physical exam and/or quality of life surveys were completed at 1, 3, 6,12, 18, 24, and 36 months, with 5-year (60-month) follow-up ongoing. A total of n = 121 patients were implanted with P4HB mesh (n = 75 (62%) female) with a mean age of 54.7 ± 12.0 years and mean BMI of 32.2 ± 4.5 kg/m2 (±standard deviation). Comorbidities included: obesity (78.5%), active smokers (23.1%), COPD (28.1%), diabetes mellitus (33.1%), immunosuppression (8.3%), coronary artery disease (21.5%), chronic corticosteroid use (5.0%), hypo-albuminemia (2.5%), advanced age (5.0%), and renal insufficiency (0.8%). Hernias were repaired via retrorectus (n = 45, 37.2% with myofascial release (MR) or n = 43, 35.5% without MR), onlay (n = 8, 6.6% with MR or n = 24, 19.8% without MR), or not reported (n = 1, 0.8%). 82 patients (67.8%) completed 36-month follow-up. 17 patients (17.9% ± 0.4%) experienced hernia recurrence at 3 years, with n = 9 in the retrorectus group and n = 8 in the onlay group. SSI (n = 11) occurred in 9.3% ± 0.03% of patients. Long-term outcomes following ventral hernia repair with P4HB mesh demonstrate low recurrence rates at 3-year (36-month) postoperative time frame with no patients developing late mesh complications or requiring mesh removal. 5-year (60-month) follow-up is ongoing.